Rani Therapeutics’ (RANI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Rani Therapeutics (NASDAQ:RANI) in a research report released on Tuesday morning, Benzinga reports. They currently have a $13.00 target price on the stock.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group lowered their price target on Rani Therapeutics from $21.00 to $9.00 and set a buy rating for the company in a research note on Wednesday, March 27th. Rodman & Renshaw assumed coverage on Rani Therapeutics in a research note on Thursday, June 13th. They issued a buy rating and a $10.00 price target for the company. Maxim Group assumed coverage on Rani Therapeutics in a research note on Friday, June 14th. They issued a buy rating and a $15.00 price target for the company. Finally, BTIG Research upped their price target on Rani Therapeutics from $7.00 to $14.00 and gave the company a buy rating in a research note on Thursday, May 9th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Rani Therapeutics currently has an average rating of Buy and an average price target of $12.29.

Rani Therapeutics Stock Performance

Shares of NASDAQ:RANI opened at $3.94 on Tuesday. The stock has a market capitalization of $198.65 million, a P/E ratio of -3.05 and a beta of 0.25. Rani Therapeutics has a 1-year low of $1.82 and a 1-year high of $8.75. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of 1.43. The business has a 50-day moving average price of $5.31 and a two-hundred day moving average price of $4.18.

Rani Therapeutics (NASDAQ:RANI) last announced its quarterly earnings data on Monday, May 6th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Equities analysts predict that Rani Therapeutics will post -1.05 earnings per share for the current year.

Institutional Trading of Rani Therapeutics

A hedge fund recently raised its stake in Rani Therapeutics stock. Vanguard Group Inc. grew its position in shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) by 2.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 685,303 shares of the company’s stock after acquiring an additional 16,956 shares during the quarter. Vanguard Group Inc. owned 1.37% of Rani Therapeutics worth $2,131,000 at the end of the most recent reporting period. 30.19% of the stock is owned by institutional investors.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.